Cargando…

Early onset cardiovascular disease related to methamphetamine use is most striking in individuals under 30: A retrospective chart review

INTRODUCTION: The illicit use of methamphetamine (MA), a dangerous psychostimulant has become a global epidemic. Studies have demonstrated a link between illicit substance use and cardiovascular consequences. The objective of this study was to assess whether MA use is associated with an early onset...

Descripción completa

Detalles Bibliográficos
Autores principales: Batra, Vinita, Murnane, Kevin S., Knox, Brianne, Edinoff, Amber N., Ghaffar, Yahya, Nussdorf, Laura, Petersen, Murray, Kaufman, Sarah E., Jiwani, Sania, Casey, Christopher A., Terhoeve, Stephanie, Alfrad Nobel Bhuiyan, Mohammad, Dominic, Paari, McNeil, Shawn, Patterson, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9127267/
https://www.ncbi.nlm.nih.gov/pubmed/35620216
http://dx.doi.org/10.1016/j.abrep.2022.100435
Descripción
Sumario:INTRODUCTION: The illicit use of methamphetamine (MA), a dangerous psychostimulant has become a global epidemic. Studies have demonstrated a link between illicit substance use and cardiovascular consequences. The objective of this study was to assess whether MA use is associated with an early onset of cardiovascular diseases (CVD). METHODS: Retrospective analysis was conducted using data collected from 1376 individuals at Louisiana State University Health Sciences Center - Shreveport between 2011 and 2020. Cardiovascular patients with and without a history of MA use were divided into the MA and Control groups. The age of CVD onset was assessed. Descriptive statistics for patient characteristics, Two Samples T-Test for continuous and Pearson's χ^2- tests for categorical variables were calculated. Hazard ratios (HR) and time ratios (TR) were calculated. RESULTS: The age of CVD onset in patients with prior MA use occurred on average 8 year earlier than the age of CVD onset (mean age ± SD = 44 ± 12.04) in controls (mean age ± SD = 52 ± 10.70) (unpaired t-test, p < 0.0001). The findings were noted in both the races (Time Ratio = 0.93, 95% CI = 0.89 to 0.97, p-value < 0.001), with a striking difference in the latency to CVD onset between Black and White subjects. A 12-fold increase in subjects who showed a premature onset of CVD (<30 years of age) in the MA group was observed. Our data analysis revealed that hypertension was the most frequently observed CVD. CONCLUSIONS: MA use likely accelerates early onset of CVD and contributes to CVD complications in young adults.